Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vera Therapeutics, Inc.VERA · Entity 4358 | Chief Regulatory Officer | August 03, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vera Therapeutics, Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 44,987 |
Reported balance
After 2026-08-03 transaction · row 1
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 44,987 · Balance 44,987 F1: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2024 Inducement Plan. 1/4th of the RSUs, rounded to the nearest whole share, vest on each of August 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.23 · Expires 2036-08-02 | Direct | 63,011 |
Reported balance
After 2026-08-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-03 · Grant · Acquired 63,011 · Balance 63,011 F2: 12/48ths of the shares subject to the stock option will vest and become exercisable on August 3, 2027, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2024 Inducement Plan. 1/4th of the RSUs, rounded to the nearest whole share, vest on each of August 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.
F2: 12/48ths of the shares subject to the stock option will vest and become exercisable on August 3, 2027, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 5, 2026 20:14 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 63,011 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0002145711-26-000002 · form4-08052026_080802.xml · derivative · entry 2 Boman Nancy Lee · CIK 0002145711 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,011 Underlying: Class A Common Stock · 63,011 shares Expires 2036-08-02 F2 · derivative.exercise_date: 12/48ths of the shares subject to the stock option will vest and become exercisable on August 3, 2027, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:14 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 44,987 | $0.00 | $0.00 |
DisclosureSEC source: 0002145711-26-000002 · form4-08052026_080802.xml · nonDerivative · entry 1 Boman Nancy Lee · CIK 0002145711 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,987 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2024 Inducement Plan. 1/4th of the RSUs, rounded to the nearest whole share, vest on each of August 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.